重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的疗效观察
|
摘要
目的观察使用重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的临床效果。方法选择我院2017年8月～2018年8月收治的80例胃肠道恶性肿瘤化疗相关性贫血患者作为研究对象,随机分为对照组和观察组,各40例。对照组患者进行常规治疗,观察组在此基础上采用重组人促红细胞生成素治疗,比较两组的临床疗效、并发症发生率,记录两组治疗前后血红蛋白、血细胞比容等指标和患者生活质量评分情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组血红蛋白、血细胞比容、血细胞计数和血小板计数水平均高于对照组,差异具有统计学意义(P<0.05);观察组患者生活质量评分高于对照组,差异具有统计学意义(P<0.05);两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的效果较好,可显著提高患者的临床疗效,改善患者贫血状况,提高其生活质量。
Objective To observe the clinical effect of recombinant human erythropoietin in the treatment of chemotherapy-associated anemia of gastrointestinal malignancies. Methods 80 patients with chemotherapy-related anemia of gastrointestinal malignancies admitted to our hospital from August 2017 to August 2018 were randomly divided into control group and observation group, 40 cases each. The patients in the control group underwent routine treatment. The observation group was treated with recombinant human erythropoietin. The clinical efficacy and complication rate of the two groups were compared. The hemoglobin, hematocrit and other indicators before and after treatment were recorded. Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant( P<0.05). The hemoglobin, hematocrit,blood cell count and platelet count of the observation group were higher than the control group,the difference was statistically significant( P<0.05); The quality of life score of the observation group was higher than that of the control group, the difference was statistically significant( P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Recombinant human erythropoietin is effective in the treatment of chemotherapy-associated anemia of gastrointestinal malignancies, which can significantly improve the clinical efficacy of patients, improve the anemia of patients and improve their quality of life.
Objective To observe the clinical effect of recombinant human erythropoietin in the treatment of chemotherapy-associated anemia of gastrointestinal malignancies. Methods 80 patients with chemotherapy-related anemia of gastrointestinal malignancies admitted to our hospital from August 2017 to August 2018 were randomly divided into control group and observation group, 40 cases each. The patients in the control group underwent routine treatment. The observation group was treated with recombinant human erythropoietin. The clinical efficacy and complication rate of the two groups were compared. The hemoglobin, hematocrit and other indicators before and after treatment were recorded. Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant( P<0.05). The hemoglobin, hematocrit,blood cell count and platelet count of the observation group were higher than the control group,the difference was statistically significant( P<0.05); The quality of life score of the observation group was higher than that of the control group, the difference was statistically significant( P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Recombinant human erythropoietin is effective in the treatment of chemotherapy-associated anemia of gastrointestinal malignancies, which can significantly improve the clinical efficacy of patients, improve the anemia of patients and improve their quality of life.
引文
[1]姜丹凤.重组人促红细胞生成素联合铁剂治疗肿瘤相关性贫血的疗效分析[J].航空航天医学杂志,2018,29(6):656-657.
[2]林长裕,何伟珊,李伟健.重组人促红细胞生成素治疗肿瘤相关性贫血的临床研究[J].中国医学创新,2015,12(14):25-27.
[3]钟明辉.重组人促红细胞生成素治疗癌性贫血的临床价值分析[J].深圳中西医结合杂志,2014,24(9):93-94.
[4]李金燕.重组人促红细胞生成素(rHuEPO)治疗癌性贫血的疗效[J].中国医药指南,2014,12(26):181-182.
[5]曾红梅.重组人促红细胞生成素联合铁剂治疗肿瘤相关性贫血的疗效分析[J].现代诊断与治疗,2013,24(6):1373-1374.
[6]宋鑫,陈剑云,魏立强.重组人促红细胞生成素联合铁剂应用于消化道肿瘤相关性贫血的研究[J].中国医师杂志,2018,20(1):114-116.
[7]赵成民,黄带发,张丽辉,等.重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的临床观察[J].中国新药杂志,2018,27(2):173-177.
[2]林长裕,何伟珊,李伟健.重组人促红细胞生成素治疗肿瘤相关性贫血的临床研究[J].中国医学创新,2015,12(14):25-27.
[3]钟明辉.重组人促红细胞生成素治疗癌性贫血的临床价值分析[J].深圳中西医结合杂志,2014,24(9):93-94.
[4]李金燕.重组人促红细胞生成素(rHuEPO)治疗癌性贫血的疗效[J].中国医药指南,2014,12(26):181-182.
[5]曾红梅.重组人促红细胞生成素联合铁剂治疗肿瘤相关性贫血的疗效分析[J].现代诊断与治疗,2013,24(6):1373-1374.
[6]宋鑫,陈剑云,魏立强.重组人促红细胞生成素联合铁剂应用于消化道肿瘤相关性贫血的研究[J].中国医师杂志,2018,20(1):114-116.
[7]赵成民,黄带发,张丽辉,等.重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的临床观察[J].中国新药杂志,2018,27(2):173-177.